A New MRI Tool that Provides Better Diagnosis and Monitoring of Dementia
NeuroQuant® is software used with MRI that automatically quantifies the volumes of the brain structures affected by Alzheimer’s disease (AD). It can be used to facilitate diagnosis, monitor progression of Alzheimer’s disease and assess the effectiveness of treatment. NeuroQuant® provides age-related brain atrophy reports and compares them to those without the disease.
Clinical Indications for NeuroQuant®
- Alzheimer’s Disease
- Memory loss
- Mild Cognitive Impairment
Advantages of an MRI with NeuroQuant®
- Patients 50 years of age or older with a diagnosis of Mild Cognitive Impairment (MCI), which is considered a possible transitional stage towards AD, can have a non-contrast MRI to quantitatively evaluate for increased brain atrophy.
- Patients can now be monitored to see if the progression is accelerating, and the rate of acceleration, to help in the early detection of the transition from MCI to AD.
- NeuroQuant® software evaluates the patient’s MRI for brain atrophy and compares the results to a FDA-approved database of people of the same age with healthy brains. It can provide an early warning for patients who have Mild Cognitive Impairment (MCI) and help doctors make a diagnosis and follow the progression of the disease. Studies have found that patients who have a small hippocampus are four times more likely to progress to AD in a few years than patients whose hippocampus is of normal size. The hippocampus in a healthy patient shrinks at about 1% per year, compared to about 5% per year in a person with AD.
If you are at risk for Alzheimer’s disease or another form of dementia, contact us to make an appointment today!
NeuroQuant® is a registered trademark of CorTechs Labs, Inc.